Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neosaxitoxin + bupivacaine + epinephrine
- Development stage
- Phase 1
- Lead developer
- Harvard University
- Modality
- Small Molecules
- Administration
- Subcutaneous, Perineural
01
Overview
**Neosaxitoxin + bupivacaine + epinephrine** is an investigational combination for local anesthesia designed to produce prolonged and potent sensory and pain blockade. Neosaxitoxin is a site 1 sodium channel blocker (saxitoxin analog), bupivacaine is an amino amide local anesthetic, and epinephrine acts as a vasoconstrictor to reduce systemic absorption and toxicity. In preclinical and Phase 1 studies, the combination leads to significantly prolonged duration and intensity of sensory blockade compared to individual agents or their binary combinations, with improved safety and reduced systemic adverse effects. The aim is to create a safer, long-lasting local anesthetic for clinical procedures and postsurgical analgesia[1][2][3].
- Other names
- NeoSTX + bupivacaine + epinephrineneosaxitoxin and bupivacaine and epinephrine
02
Targets
KATP channel (ATP-sensitive potassium channel)ADRA2A (α2A)ADRB1 (β1)NMDAR (Glutamate receptor ionotropic, NMDA)ADRA1A (α1A)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)
Beyond the preview
Go deeper on neosaxitoxin + bupivacaine + epinephrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neosaxitoxin + bupivacaine + epinephrine.